PFIZER2024-07-012024-09-30 PFIZER2024-07-012024-09-30 PFIZER2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member PFIZER2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member PFIZER2024-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500680 PFIZER NA Pfizer Limited Equity 2024-04-01 2025-03-31 2024-10-28 2024-10-21 INR Crores Half yearly 15:00:00 17:45:00 2024-10-28 2024-10-28 true Cash Flow Indirect Not applicable Single segment Pharmaceuticals 2024-07-01 2024-09-30 Unaudited Standalone 5885900000.00 430700000.00 6316600000.00 766500000.00 806500000.00 534200000.00 1007600000.00 21000000.00 149900000.00 878600000.00 4164300000.00 2152300000.00 0.00 2152300000.00 598900000.00 -30100000.00 568800000.00 0.00 1583500000.00 0.00 0.00 0.00 0.00 1583500000.00 -5300000.00 1578200000.00 0.00 0.00 457500000.00 10 34.61 0.00 0.00 0.00 34.61 0.00 1. The above financial results were reviewed by the Audit Committee, and thereafter approved by the Board of Directors at their meeting held on October 28, 2024. 2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). 3. The financial results for the quarter and six months ended September 30, 2024 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in 4. Exceptional item for the year ended March 31, 2024 is in relation to provision for old pending VAT / CST litigations. The Company opted for Maharashtra VAT Amnesty Scheme for certain years and had received final settlement orders. Pursuant to the said orders the Company had written back excess provision of Rs.7.95 crore. 5.The shareholders in its Annual General Meeting held on August 28, 2024 had approved a dividend of Rs.35 (350%) per equity share of Rs.10 each for the financial year ended March 31, 2024. The said dividend was paid on September 06, 2024. 6.The Company had intended to sell the Lease of MIDC Land and Sale of Buildings constructed on such land and accordingly, was classified as Asset held for sale as at 31 March 2023. During the quarter ended December 31, 2023 the Company had entered into an agreement to assign and assume the Lease of MIDC Land and Sale of Buildings constructed on such land for transferring and assigning Pfizer's unexpired leasehold rights in the land situated at Thane and sale of structures and buildings constructed thereon, to Zoetis Pharmaceutical Research Private Limited, for a lumpsum consideration of Rs.264.40 crore, of which Rs.52.88 crore has been received as an advance. Completion of transaction is subject to requisite approvals from concerned regulatory authorities, including the Maharashtra Industrial Development Corporation and accordingly, no effect of the said agreement has been given in these financial results. The said land and buildings have been classified as asset held for sale as at September 30, 2024. 7.The Company has only one segment which is ‘Pharmaceuticals’. Therefore disclosure relating to segments is not applicable and accordingly not made. Single segment 2024-04-01 2024-09-30 Unaudited Standalone 11514500000.00 849100000.00 12363600000.00 1343900000.00 2682400000.00 87800000.00 1921300000.00 42100000.00 295900000.00 1811700000.00 8185100000.00 4178500000.00 0.00 4178500000.00 1149400000.00 -61500000.00 1087900000.00 0.00 3090600000.00 0.00 0.00 0.00 0.00 3090600000.00 -10700000.00 3079900000.00 0.00 0.00 457500000.00 10 67.55 0.00 0.00 0.00 67.55 0.00 Other expenses 878600000.00 Other expenses 1811700000.00 1324500000.00 28200000.00 0.00 5274900000.00 292900000.00 0.00 0.00 0.00 0.00 0.00 0.00 121300000.00 121300000.00 604600000.00 6394800000.00 14041200000.00 4548200000.00 0.00 2275100000.00 353400000.00 22459800000.00 0.00 224400000.00 25312700000.00 0.00 366400000.00 30227300000.00 317500000.00 0.00 44586000000.00 457500000.00 37051200000.00 37508700000.00 37508700000.00 0.00 0.00 377600000.00 377600000.00 653100000.00 0.00 0.00 0.00 1030700000.00 25000000.00 1813100000.00 972200000.00 2810300000.00 841300000.00 574300000.00 1820700000.00 0.00 6046600000.00 0.00 0.00 7077300000.00 44586000000.00 42100000.00 -211300000.00 -406000000.00 0.00 201300000.00 382400000.00 26000000.00 -28200000.00 0.00 145770000.00 0.00 -134600000.00 0.00 295900000.00 0.00 124400000.00 315500000.00 242700000.00 0.00 1100000.00 0.00 765700000.00 74500000.00 0.00 0.00 -65100000.00 0.00 4200000.00 0.00 244970000.00 4423470000.00 0.00 0.00 0.00 929200000.00 0.00 3494270000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 90600000.00 120000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 611900000.00 0.00 -2963500000.00 0.00 -2442080000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 189400000.00 1591100000.00 38300000.00 0.00 0.00 -1818800000.00 -766610000.00 0.00 -766610000.00 0.00 -766610000.00 7100000.00 14300000.00 -1800000.00 -3600000.00